Aptamer Group

Vipergen is a world leading provider of small molecule drug discovery services based on DNA-encoded library (DEL) technologies.

Vipergen is finding tractable hits/leads for your pharmaceutical relevant targets, using three proprietary 2nd and 3rd generation DEL technologies.

Vipergen is offering different business models, including simple Fee-For-Service.

Recent News
- Copenhagen, Denmark, November 6th, 2020 - Commercial release of the first technology for DEL screening inside a living cell - Vipergen ApS announced today the commercial release of the first technology for screening of DNA-encoded small molecule libraries (DELs) inside a living cell. This proprietary technology will significantly accelerate and improve the drug discovery process.

YoctoReactor® – Technology platform for synthesizing DNA-encoded chemical libraries
• 100% match between the DNA-code and the synthesized small molecule is ensured by purification steps after each chemical reaction (unique capability) and use of robust chemistries

Binder Trap Enrichment® – Technology platform for DEL screening in a homogeneous assay
• As a homogeneous assay, BTE delivers high fidelity and a low false positive rate by avoiding surface artifacts and the complexity of matrix binding
• Instant specificity – multiplexed screening of target and anti-targets (unique capability)

Cellular Binder Trap Enrichment® – Technology platform for DEL screening in a living cell
• As an in vivo assay, cBTE delivers lower attrition rate (unique capability)
• No need for purified active target protein – cBTE accommodates a broader target space (unique capability)

Novascon Pharmaceuticals Sp. z o.o. to jedna z najdynamiczniej rozwijających się firm działających na polskim rynku aptecznym już od 10 lat.

Według danych renomowanej firmy IMS Health, Novascon Pharmaceuticals zajmuje 40. pozycję w gronie największych firm oferujących produkty dostępne bez recepty oraz 14. pozycję w gronie firm oferujących suplementy diety. Jest spółką o stałym przyroście sprzedaży w stosunku do roku poprzedniego.*

Firma specjalizuje się w opracowywaniu i wprowadzaniu na rynek nowatorskich suplementów diety, dietetycznych środków spożywczych specjalnego przeznaczenia medycznego oraz wyrobów medycznych. W jej ofercie znajduje się blisko 40 innowacyjnych produktów o szerokim zakresie zastosowania. Najbardziej znane marki spółki to Detramax, Insulan, Floractin, Polomag, Ceviforte, Tonaxinum.

Zgodnie ze swoją misją Novascon Pharmaceuticals opracowuje zarówno produkty dla niemowląt i dzieci, jak też osób dorosłych, gdyż niezależnie od wieku każdy potrzebuje ważnych dla zdrowia substancji odżywczych. Od chwili rozpoczęcia działalności w 2007 roku firma łączy nowoczesną technologię z najwyższą jakością, respektując w ten sposób zasadę: najważniejsze jest zdrowie.

Atuty firmy to zespół zaangażowanych profesjonalistów, nowoczesne zaplecze technologiczne, konsekwentnie realizowana wizja rozwoju firmy. Firma planuje dalej poszerzać swoje portfolio, w tym również o preparaty o statusie leków.

Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) is a biotechnology company that deploys its extensive knowledge base and portfolio of compounds to develop first-in-class immunomodulatory treatments for specialist oncology and immunology indications with a high unmet medical need and significant commercial potential. Following a portfolio refocus, the business model of Active Biotech aims to advance projects to the clinical development phase and then further develop the programs internally or pursue in partnership. Active Biotech currently holds three projects in its portfolio: Naptumomab, a targeted anti-cancer immunotherapy, partnered to NeoTX Therapeutics, is in a phase Ib/II clinical program in patients with advanced solid tumors. The small molecule immunomodulators, tasquinimod and laquinimod, both having a mode of actions that includes modulation of myeloid immune cell function, are targeted towards hematological malignancies and inflammatory eye disorders, respectively. Tasquinimod, is in clinical phase Ib/IIa for treatment of multiple myeloma. Laquinimod is advancing to a clinical phase I study with a topical ophthalmic formulation, to be followed by phase II for treatment of non-infectious uveitis. Please visit www.activebiotech.com for more information.

Adaltis S.r.l. is an international IVD company headquartered in Rome, Italy.

Adaltis develops, manufactures and markets in-vitro diagnostic systems and reagents to detect viral infections, diagnose immune system diseases and measure human hormone responses.

http://www.adaltis.net/products/

Personal LAB - fully automated 2 plate microELISA/IFA analyser
NEXgen - fully automated 7 plate microELISA / IFA analyser
EXTRAlab - Robotic systems for liquid handling, extraction/purification of nucleic acids
Pchem Family - clinical chemistry systems for 120-500 tests/hour
(Instruments and dedicated reagents).
HEMO One - Point of Care Analyser (Diabetes / Vitamin deficiencies / Metabolic disorders / Inflammatory diseases)

With more than 10 thousands of instruments installed worldwide, Adaltis is known for excellence in performance and innovation.

Adaltis’ development and production of reagents include a wide range of assays:
- Diagnostic kits for detection of infection agents by real-time PCR (MOLgen Line)
- MicroELISA kits (EIAgen)
- Clinical Chemistry / Turbidity / Latex (CHEMgen)
- Genomics & Bioinformatics

MDx kits and reagents for DNA/RNA complete extraction kits providing a wide range of clinical specimens (liquids, tissue, cells etc.), compatible with most DNA extraction kits on market.

Adaltis provides:
Dedicated Customized Services and Antibody Production.
Adaltis has a strong record in OEM / ODM development and production of systems and kits. Well known partners have experienced and enjoy the expertise and quality products of Adaltis.

Adaltis is ISO 9001 and ISO 13485 certified. Our products are IVD-CE marked.

All of our products are backed by dedicated application support and technical service.

Customer Care Center:
info@adaltis.net

Sales and Marketing Office:
sales@adaltis.net

Order Handling and Logistics:
order@adaltis.net

Tel: + 39 0774 5791

Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders. Allosteric modulators offer several potential advantages over conventional non-allosteric molecules and may offer an improved therapeutic approach to conventional "orthosteric" small molecule or biological drugs. Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention. Addex's lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is poised to start a pivotal registration clinical trial for Parkinson’s disease levodopa induced dyskinesia (PD-LID) in H1 2021. Addex is also investigating dipraglurant's therapeutic use in blepharospasm (a type of dystonia), for which a clinical trial is expected to be initiated in H1 2021. Addex's third clinical program, ADX71149 (mGlu2 positive allosteric modulator or PAM), developed in collaboration with Janssen Pharmaceuticals, Inc., is scheduled to enter a phase 2a proof of concept clinical study for the treatment of epilepsy in H1 2021. Addex’s GABAB PAM program has been licensed to Indivior PLC for the treatment of addiction. Preclinical programs include GABAB PAM for CMT1A, mGlu7 NAM for PTSD, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders. Addex is listed on the SIX Swiss Exchange and NASDAQ Capital Market, and trades under the ticker symbol "ADXN".